Dedicated to primary cells
Product and service development

Dedicated to the development of primary cell products and services

Learn More
Dedicated to primary cells
Product and service development

Dedicated to the development of primary cell products and services

Learn More
Dedicated to primary cells
Product and service development

Dedicated to the development of primary cell products and services

Learn More
scroll down

About Us

Dedicated to primary cells
Product and Service Development

Wuxi Hycells Biotechnology Co., Ltd. is an innovative biotechnology company specializing in primary cells, related reagents, and technical services. With a long-standing commitment to the fields of cell and gene therapy (CGT) and large-molecule therapeutics, the team is dedicated to providing customers with end-to-end, one-stop solutions for primary cell products—covering research and development, manufacturing, sales, and technical support.

View more

Product Center

Quality first, innovation oriented

Cultivation Products

.

Culture products generally refer to various reagents, consumables and equipment used for in vitro culture, expansion and maintenance of cells, and are widely used in scientific research, drug development, vaccine production, cell therapy and other fields.

Obtain Solutions →

Testing Products

.

Hycells is committed to becoming a leading global one-stop supplier of primary cells, related reagents, and services.

Obtain Solutions →

Other Products And Instruments

.

Hycells is committed to becoming a leading global one-stop supplier of primary cells, related reagents, and services.

Obtain Solutions →

Cultivation Products

Cultivation Products

Testing Products

Testing Products

Other Products And Instruments

Other Products And Instruments

Our Advantages

Primary Cells, Pharmacological Efficacy Services, and Product Services
One-Stop Expert in Upstream Cell Solutions

Quality

High-quality technical standards

Professional

Professional laboratory research team

Compliance

Clinical Sample Collection Compliance System

After-sales

A comprehensive after-sales service system

News Updates

Stay updated on He Yousheng’s latest news

This training program focuses on the regulatory standards governing the manufacturing of cell therapy products and the clinical research and translational applications of cutting-edge biomedical technologies, attracting participants from enterprises, research institutes, clinical institutions, and industry-chain representatives across the country. Standardization is the fundamental cornerstone for ensuring that these products are safe, effective, and accessible. As a one-stop upstream cell solutions provider offering primary cell services, pharmacological efficacy services, and product services, Heyousheng looks forward to engaging in in-depth exchanges with industry experts and peers.

HeYouSheng Bio’s 3.0 High-Efficiency HiXpan® NK Serum-Free Culture Kit is manufactured in strict compliance with GMP standards, and its production system adheres to relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade manufacturing and applications. In response to extensive customer demand, we have conducted a comparative analysis of culture performance against two leading commercial competitor media.

HeYouSheng Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the PBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering PBMC seed stocks or directly and efficiently expanding fresh PBMCs, to ultimately obtaining NK cells with high purity and high viability.

HeYouSheng Biotechnology, in collaboration with Boteng Biotechnology, has pioneered the launch of PBMCs that comply with both GMP standards and the dual China–U.S. regulatory submission requirements, thereby establishing a robust compliance foundation for iPSC reprogramming right at the source. The notion of “starting from ‘zero’” not only signifies the proactive avoidance of compliance risks from the very outset of R&D, but also reflects the establishment by the two companies of a comprehensive, end-to-end compliance closed-loop that spans the entire process—from donor screening and sample collection to isolation, preparation, and quality control.

The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire process as an inviolable baseline, and centers on differentiated technological innovation as the core driver. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and innovation-oriented guidance for the future direction of the industry.

From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.

Quickly access products and solutions

Currently, Heyousheng has established nearly 1,000 square meters of R&D laboratories and has officially obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. The company has also been recognized as a “Shanghai High-Tech Enterprise” and a “Shanghai Specialized, Sophisticated, Distinctive, and Innovative SME.” Heyousheng is committed to becoming a world-leading one-stop supplier of primary cells, associated reagents, and related services.